Skip to main content

Semaglutide News (Page 5)

Semaglutide May Lower Risk for Opioid Overdose in T2DM, Opioid Use Disorder

WEDNESDAY, Sept. 25, 2024 – For patients with type 2 diabetes (T2D) and opioid use disorder (OUD), semaglutide is associated with a significantly lower risk for opioid overdose compared with other...

Weight Reduction Varies for Patients Receiving Semaglutide, Liraglutide

FRIDAY, Sept. 13, 2024 – For patients with obesity receiving semaglutide or liraglutide, weight reduction at one year is associated with medication active agent, dosage, treatment indication, and...

Semaglutide Does Not Increase Psychiatric Complications in Overweight, Obesity

TUESDAY, Sept. 3, 2024 – Treatment with semaglutide does not increase the risk for developing symptoms of depression or suicidal ideation/behavior among adults with overweight or obesity, according...

Semaglutide Reduces Risk for MACE in Patients With Obesity and Heart Failure

WEDNESDAY, Aug. 28, 2024 – Semaglutide reduces the risk for major adverse cardiovascular events (MACE) and composite heart failure end points compared with placebo in patients with overweight or...

After Weighting, 3.6 Million Likely to Be Newly Eligible for Semaglutide

MONDAY, Aug. 26, 2024 – Increases in eligibility for semaglutide are discussed in a research letter published online Aug. 27 in the Annals of Internal Medicine. After the Semaglutide Effects on...

Semaglutide-Linked Suicidal Ideation ID'd in Disproportionality Analysis

WEDNESDAY, Aug. 21, 2024 – Semaglutide-associated suicidal ideation has been identified in a disproportionality analysis, according to a study published online Aug. 20 in JAMA Network Open. Georgios...

GLP-1 RA Use Linked to Lower Rates of Hyperkalemia in Type 2 Diabetes

MONDAY, Aug. 12, 2024 – Treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and a lower rate of renin-angiotensin system inhibitor...

Cost Keeps Many Who Need Them From Getting New Weight-Loss Meds

WEDNESDAY, Aug. 7, 2024 (HealthDay news) – Medicare and Medicaid patients are less likely to get cutting-edge weight-loss drugs than people with private insurance are, a new study finds. Medicaid...

2021 to 2023 Saw Considerable Increase in Semaglutide Fills

MONDAY, Aug. 5, 2024 – From 2021 through 2023, there was a considerable increase in the number of semaglutide fills, according to a research letter published online Aug. 2 in JAMA Health Forum....

Semaglutide Products Being Sold Online Without Prescriptions

FRIDAY, Aug. 2, 2024 – Semaglutide products are being sold online, with products likely unregistered or unlicensed, according to a research letter published online Aug. 2 in JAMA Network Open. Amir...

Semaglutide Seems Beneficial for Comorbid T2DM, Tobacco Use Disorder

MONDAY, July 29, 2024 – For patients with type 2 diabetes mellitus (T2DM) and tobacco use disorder (TUD), new use of semaglutide is associated with lower risk of TUD-related health care measures...

FDA Warns of Accidental Overdoses from Compounded Versions of Ozempic

TUESDAY, July 30, 2024 – People taking compounded versions of Ozempic have been overdosing on the drug, the U.S. Food and Drug Administration warns. These ODs typically are due to miscommunications...

Only One-Quarter of Patients Still Taking Semaglutide for Weight Loss Two Years Later

FRIDAY, July 12, 2024 – Three of four patients stop taking semaglutide (Ozempic or Wegovy) two years after being prescribed the glucagon-like peptide-1 receptor agonist (GLP-1 RA) for weight loss,...

GLP-1 RAs May Reduce Risk for Some Obesity-Linked Cancers Versus Insulin in T2D

THURSDAY, July 11, 2024 – For patients with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for 10 of 13 obesity-associated cancers...

Significantly More Weight Loss Seen With Tirzepatide Versus Semaglutide

MONDAY, July 8, 2024 – Tirzepatide is associated with significantly greater weight loss than semaglutide for adults with overweight or obesity, according to a study published online July 8 in JAMA...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction, Chronic Kidney Disease, Diabetes, Type 2

Related drug support groups

Ozempic, Wegovy, Rybelsus

Semaglutide patient information at Drugs.com